BioPhotas has introduced Celluma POD, a light therapy medical device.

The unit is the latest addition to its Celluma Series, which was developed in the US.

Celluma POD has been cleared by the US Food and Drug Administration (FDA) and incorporates the features of the Celluma PRO into a smaller handheld device used to treat skin, joint and muscle conditions.

The indications-for-use include the treatment of peri-orbital and full-face wrinkles, acne, muscle and joint pain, muscle tissue tension and spasms, arthritis, and compromised local blood circulation.

“The Celluma POD has three separate programmes all in a single device for treating acne, wrinkles and musculoskeletal pain in a targeted fashion.”

BioPhotas president and CEO Patrick Johnson said: “Leveraging the clinically-proven performance of our LED panel devices, we are introducing a handheld LED device that is different from any other device available on the market today.

“Typically, handheld light therapy devices are configured for a single purpose such as treating pain or acne.

“However, the Celluma POD has three separate programmes all in a single device for treating acne, wrinkles and musculoskeletal pain in a targeted fashion.”

According to a research conducted by NASA, the Celluma Series utilises blue, red and near-infrared light energy to safely address a wide range of musculoskeletal and dermatological conditions. Each wavelength is absorbed by different molecules, which act as a signalling mechanism for varied cellular processes and results in reduced inflammation, enhanced micro-circulation and increased collagen production to facilitate fast cellular healing.

Delivery of the new Celluma POD is expected to commence later this month.